Dashboard
1
With a growth in Net Profit of 806.57%, the company declared Very Positive results in Mar 25
- The company has declared positive results in Jan 70 after 5 consecutive negative quarters
- PRE-TAX PROFIT(Q) At CNY 87.96 MM has Grown at 232.09%
- NET PROFIT(Q) At CNY 109.53 MM has Grown at 1,115.99%
- NET SALES(Q) At CNY 646.89 MM has Grown at 29.67%
2
With ROE of 6.45%, it has a fair valuation with a 2.66 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 16,685 Million (Large Cap)
41.00
NA
2.99%
-0.13
16.98%
2.34
Revenue and Profits:
Net Sales:
806 Million
(Quarterly Results - Sep 2025)
Net Profit:
980 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.43%
0%
-1.43%
6 Months
5.52%
0%
5.52%
1 Year
16.91%
0%
16.91%
2 Years
0.56%
0%
0.56%
3 Years
-9.74%
0%
-9.74%
4 Years
-11.43%
0%
-11.43%
5 Years
-22.57%
0%
-22.57%
Tonghua Dongbao Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-1.27%
EBIT Growth (5y)
-19.10%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
0.01
Sales to Capital Employed (avg)
0.36
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
17.69%
ROE (avg)
17.19%
Valuation key factors
Factor
Value
P/E Ratio
41
Industry P/E
Price to Book Value
2.66
EV to EBIT
48.39
EV to EBITDA
26.90
EV to Capital Employed
2.75
EV to Sales
6.07
PEG Ratio
NA
Dividend Yield
3.06%
ROCE (Latest)
5.68%
ROE (Latest)
6.45%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
806.10
719.20
12.08%
Operating Profit (PBDIT) excl Other Income
127.80
189.00
-32.38%
Interest
5.70
5.80
-1.72%
Exceptional Items
0.00
0.00
Consolidate Net Profit
979.60
101.50
865.12%
Operating Profit Margin (Excl OI)
158.50%
154.60%
0.39%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 12.08% vs 11.18% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 865.12% vs -4.87% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,004.10
3,070.20
-34.72%
Operating Profit (PBDIT) excl Other Income
317.60
1,477.60
-78.51%
Interest
14.80
7.20
105.56%
Exceptional Items
-135.30
-6.50
-1,981.54%
Consolidate Net Profit
-44.10
1,167.90
-103.78%
Operating Profit Margin (Excl OI)
56.20%
413.80%
-35.76%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -34.72% vs 10.73% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -103.78% vs -26.17% in Dec 2023
About Tonghua Dongbao Pharmaceutical Co., Ltd. 
Tonghua Dongbao Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






